News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
405,248 Results
Type
Article (26562)
Company Profile (62)
Press Release (378624)
Multimedia
Podcasts (28)
Webinars (7)
Section
Business (110824)
Career Advice (555)
Deals (18634)
Drug Delivery (53)
Drug Development (49599)
Employer Resources (53)
FDA (12576)
Job Trends (8893)
News (196773)
Policy (20177)
Tag
Academia (1804)
Accelerated approval (3)
Adcomms (8)
Allergies (74)
Alliances (28714)
ALS (65)
Alzheimer's disease (837)
Antibody-drug conjugate (ADC) (67)
Approvals (12634)
Artificial intelligence (186)
Autoimmune disease (11)
Automation (5)
Bankruptcy (149)
Best Places to Work (7280)
BIOSECURE Act (5)
Biosimilars (38)
Biotechnology (43)
Bladder cancer (59)
Brain cancer (18)
Breast cancer (206)
Cancer (1534)
Cardiovascular disease (123)
Career advice (480)
Career pathing (13)
CAR-T (84)
Cell therapy (235)
Cervical cancer (14)
Clinical research (42140)
Collaboration (487)
Compensation (171)
Complete response letters (9)
COVID-19 (1531)
CRISPR (16)
C-suite (150)
Cystic fibrosis (50)
Data (1658)
Decentralized trials (2)
Denatured (20)
Depression (33)
Diabetes (185)
Diagnostics (3843)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (16)
Drug discovery (58)
Drug pricing (58)
Drug shortages (21)
Duchenne muscular dystrophy (58)
Earnings (40354)
Editorial (23)
Employer branding (8)
Employer resources (49)
Events (55358)
Executive appointments (470)
FDA (13664)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (434)
Gene editing (49)
Generative AI (13)
Gene therapy (141)
GLP-1 (415)
Government (3084)
Grass and pollen (3)
Guidances (101)
Healthcare (12633)
Huntington's disease (10)
IgA nephropathy (17)
Immunology and inflammation (44)
Indications (20)
Infectious disease (1605)
Inflammatory bowel disease (85)
Inflation Reduction Act (5)
Influenza (28)
Intellectual property (53)
Interviews (51)
IPO (8054)
IRA (20)
Job creations (1908)
Job search strategy (438)
Kidney cancer (7)
Labor market (13)
Layoffs (177)
Leadership (4)
Legal (3825)
Liver cancer (57)
Lung cancer (242)
Lymphoma (105)
Machine learning (5)
Management (19)
Manufacturing (122)
MASH (53)
Medical device (13046)
Medtech (13049)
Mergers & acquisitions (10929)
Metabolic disorders (456)
Multiple sclerosis (62)
NASH (11)
Neurodegenerative disease (50)
Neuropsychiatric disorders (10)
Neuroscience (1204)
NextGen: Class of 2025 (4134)
Non-profit (2898)
Now hiring (17)
Obesity (227)
Opinion (78)
Ovarian cancer (58)
Pain (66)
Pancreatic cancer (57)
Parkinson's disease (97)
Partnered (11)
Patents (130)
Patient recruitment (87)
Peanut (37)
People (35858)
Pharmaceutical (21)
Pharmacy benefit managers (12)
Phase I (12152)
Phase II (18227)
Phase III (14930)
Pipeline (837)
Policy (64)
Postmarket research (1704)
Preclinical (3968)
Press Release (19)
Prostate cancer (77)
Psychedelics (19)
Radiopharmaceuticals (166)
Rare diseases (207)
Real estate (3020)
Recruiting (20)
Regulatory (14783)
Reports (17)
Research institute (1649)
Resumes & cover letters (88)
Rett syndrome (4)
RNA editing (2)
RSV (20)
Schizophrenia (52)
Series A (69)
Series B (53)
Service/supplier (3)
Sickle cell disease (29)
Special edition (4)
Spinal muscular atrophy (103)
Sponsored (13)
Startups (2200)
Stomach cancer (8)
Supply chain (39)
Tariffs (14)
The Weekly (8)
Vaccines (369)
Venture capitalists (14)
Weight loss (142)
Women's health (19)
Worklife (4)
Date
Last 7 days (513)
Last 30 days (1692)
Last 365 days (19453)
2025 (6837)
2024 (21167)
2023 (24217)
2022 (32388)
2021 (34866)
2020 (33909)
2019 (29777)
2018 (22875)
2017 (19987)
2016 (19117)
2015 (22450)
2014 (16912)
2013 (14038)
2012 (15190)
2011 (15583)
2010 (14094)
Location
Africa (382)
Alabama (19)
Alaska (2)
Arizona (121)
Arkansas (10)
Asia (25469)
Australia (4060)
California (3430)
Canada (1343)
China (387)
Colorado (176)
Connecticut (203)
Delaware (124)
Europe (50695)
Florida (587)
Georgia (132)
Idaho (35)
Illinois (380)
India (14)
Indiana (235)
Iowa (3)
Japan (129)
Kansas (75)
Kentucky (14)
Louisiana (8)
Maine (27)
Maryland (670)
Massachusetts (2424)
Michigan (113)
Minnesota (279)
Mississippi (2)
Missouri (55)
Montana (18)
Nebraska (19)
Nevada (38)
New Hampshire (60)
New Jersey (1200)
New Mexico (11)
New York (1025)
North Carolina (579)
North Dakota (6)
Northern California (1529)
Ohio (143)
Oklahoma (3)
Oregon (25)
Pennsylvania (891)
Puerto Rico (7)
Rhode Island (24)
South America (550)
South Carolina (23)
Southern California (1308)
Tennessee (80)
Texas (621)
United States (14015)
Utah (130)
Virginia (85)
Washington D.C. (43)
Washington State (264)
West Virginia (3)
Wisconsin (45)
405,248 Results for "oncosec medical incorporated".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec) today announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023.
May 16, 2023
·
8 min read
Press Releases
Rimkus Acquires Human Factors Consulting Services, Incorporated, Enhancing Expertise in Human Factors and Medical Device Consulting
March 6, 2025
·
2 min read
Biotech Beach
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
OncoSec Medical Incorporated today announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).
April 27, 2023
·
5 min read
Biotech Beach
OncoSec Announces Reverse Stock Split - November 08, 2022
OncoSec Medical Incorporated announced it intends to effect a 1-for-22 reverse split of its issued and outstanding common stock.
November 8, 2022
·
4 min read
Biotech Beach
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules.
May 18, 2023
·
7 min read
Biotech Beach
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Medical Incorporated announced the closing of its previously announced registered direct offering of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, priced at-the-market under Nasdaq rules.
April 11, 2023
·
6 min read
Drug Development
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
OncoSec Medical Incorporated (NASDAQ: ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease, today announced primary endpoint data from the Phase 2 KEYNOTE-695 clinical trial.
April 3, 2023
·
8 min read
Biotech Beach
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
OncoSec Medical Incorporated announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, in a registered direct offering priced at-the-market under Nasdaq rules.
April 10, 2023
·
7 min read
Biotech Beach
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”) today announced early clinical data from an investigator-sponsored trial (IST) conducted by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute.
November 15, 2022
·
7 min read
Business
OncoSec Announces Pipeline Prioritization and Workforce Reduction
OncoSec Medical Incorporated announced a corporate restructuring intended to prioritize development of its lead clinical candidate TAVO™ a plasmid encoding interleukin 12 delivered by intratumoral electroporation, and extend the Company’s cash runway.
October 4, 2022
·
5 min read
1 of 40,525
Next
